A capsule refers to the growth of scar tissue around the breast implant. It is natural for the body to develop scar tissue around an implant and has the advantage of holding the implant in place. However, this capsule of scar tissue can harden and cause discomfort, called capsular contracture. Therefore, a capsulectomy is the surgical procedure wherein this scar tissue is removed to relieve pain and discomfort and restore a natural look to the breast.
An en bloc capsulectomy is the removal of the capsule and scar tissue surrounding along with the implant, or “en bloc.” The procedure may be necessary in cases of a ruptured implant, capsular contracture, or other problems affecting the look or comfort of breast implants.
A total capsulectomy is the removal of the implant and the surrounding scar tissue or capsule. It does not necessarily mean the surgeon will remove the breast implant within the capsule in an “en bloc” procedure.
Breast implants may be removed, or explanted, in a similar manner as they were placed, in reverse. In most cases, the procedure is performed while you are under intravenous sedation. Your surgeon will make an incision in the areola or the crease beneath the breast (inframammary) to remove the implants. If you are having an en bloc capsulectomy, your surgeon will most likely make an inframammary incision to remove the entire implant and scar tissue.
You may choose to undergo a breast lift after the implants and scar tissue have been removed to help tighten any loose skin. The procedure takes from one to three hours, and most patients can return home following surgery.
As with most surgeries requiring incisions, you will have scars. However, Dr. Rottman is exceptionally skilled at hiding and closing incisions for minimal scarring, which will fade over time.
The recovery from breast implant removal or en bloc capsulectomy is similar to that of breast augmentation. In the case of simple breast implant removal, it may be an easier recovery you’re your initial breast augmentation, while en bloc procedures may take a bit longer. You may have drains that Dr. Rottman will advise you on how to care for and you will need to take a week off from work to heal.
In late July of this year, Allergan voluntarily recalled their BIOCELL textured implants and tissue expanders under the name Natrelle after receiving a request for recall from the FDA. The recall is not a cause for alarm. Macro-textured implants of the recalled style are not common in the United States, making up only 5% of implants.
Textured implants are saline or silicone implants with a textured, granular, or rough surface to adhere to the tissue around the implant. This adherence to the surrounding tissue keeps implants from rotating or moving after implantation, which is especially helpful for teardrop-shaped implants.
Macro-textured implants, such as those recalled by Allergan, have rougher, more textured surface than other textured implants. The particular implants and tissue expanders recalled are as follows:
Allergan BIOCELL textured implants were recalled as it was found that these particular implants have a slightly higher chance of leading to the development of BIA-ALCL (breast implant-associated anaplastic large cell lymphoma).
BIA-ALCL is a rare non-Hodgkin’s form of lymphoma that grows very slowly, making it easy to catch as well as treat. The symptoms of BIA-ALCL are a persistent swelling, fluid developing around the implant, pain, or a firm or hard lump in the breast area.
While the likelihood of developing BIA-ALCL is slightly higher with these textured implants, it is still infrequent, and highly unlikely to occur. However, if you have noticed any of the above symptoms, you should speak with your doctor immediately so that testing can be performed.
One theory is that macro-textured implants can lead to a higher probability of BIA-ALCL due to inflammation or bacteria. The rough texture and crevices in these implants may create an environment where bacteria can thrive and spread. To date, it is uncertain why some women develop BIA-ALCL, and further studies are needed.
The FDA does not recommend the removal of recalled implants unless you are experiencing the symptoms of BIA-ALCL. While there is a higher likelihood of developing BIA-ALCL from macro-textured implants, it is still very rare. However, it is advised that you speak with your surgeon to discuss what route will be best for you.
If you are already thinking of breast implant removal or replacement, or the need to remove scar tissue from around your implants, this could be the time to look at scheduling a consultation. Please reach out to Dr. Rottman and his team to schedule a consultation to learn more about your options.
© Rottman Plastic Surgery. All rights reserved.
Alt phone: 410-321-6868
As our community copes with fast-moving spread of the COVID-19 coronavirus we hope you and yours are in good health during these stressful times.
Public officials have asked businesses to close down for a limited tune while a local quarantine begins. To do our part in ensuring health and safety of everyone on our staff and all of our patients and their families, Rottman Plastic Surgery will be closing temporarily starting Friday, March 20, 2020.
We will be closed next week for all in-person consultations and appointments and will reassess each week thereafter. However, we will remain open for daily virtual consultations and all postoperative follow-up care that is needed.
If you were originally scheduled for a consultation and would like to do a virtual one with Dr. Rottman, please call 410-297-0831 to schedule the virtual consultation.
Our office will be contacting all patients who were currently scheduled to reschedule.
We are monitoring this situation on a daily basis. When we are given the green-light to renew business operations we will update you. We thank you for your patience during this interruption and hope to see when we re-open, happy and healthy.
Please contact us at 410-297-0831 if you have any questions and we will respond back as quickly as we can. Thank you again, and stay well.
Steven J Rottman, MD.